Alto Neuroscience, Inc. (NYSE:ANRO) Receives $33.80 Consensus Target Price from Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given a consensus recommendation of “Buy” by the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $33.80.

Several research analysts have recently commented on ANRO shares. Wedbush reiterated an “outperform” rating and set a $29.00 price target on shares of Alto Neuroscience in a report on Tuesday, September 10th. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Finally, Rodman & Renshaw assumed coverage on shares of Alto Neuroscience in a report on Friday, June 21st. They set a “buy” rating and a $43.00 price target for the company.

Insider Transactions at Alto Neuroscience

In other news, insider Adam Savitz acquired 12,069 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The shares were purchased at an average price of $12.60 per share, for a total transaction of $152,069.40. Following the acquisition, the insider now owns 36,920 shares of the company’s stock, valued at $465,192. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds have recently added to or reduced their stakes in ANRO. RA Capital Management L.P. purchased a new stake in shares of Alto Neuroscience during the first quarter worth $21,267,000. Price T Rowe Associates Inc. MD purchased a new stake in Alto Neuroscience during the 1st quarter worth about $9,788,000. Vanguard Group Inc. purchased a new position in shares of Alto Neuroscience in the 1st quarter valued at about $8,233,000. Jennison Associates LLC acquired a new position in shares of Alto Neuroscience during the first quarter worth about $7,039,000. Finally, Artal Group S.A. acquired a new position in shares of Alto Neuroscience during the first quarter worth about $5,372,000.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $10.19 on Friday. The firm has a 50-day simple moving average of $11.61 and a 200-day simple moving average of $12.77. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04. Alto Neuroscience has a 52 week low of $7.91 and a 52 week high of $24.00.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. Equities research analysts predict that Alto Neuroscience will post -2.63 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.